기업악재
Novartis M&A strategy questioned, shareholders push governance reform after trial setbacks영어 원문
ALS drug failure intensifies scrutiny of Novartis R&D and M&A strategy, shareholder pressure persists
첫날 +0.0% · 5일 후 +2.5%
›전개 과정 3회
- 2026-09-10 After trial setbacks and $30B market cap loss, governance under fire; company reiterates guidance
- 2026-09-11 Multiple sources report investor scrutiny of M&A following trial setbacks, echoing existing event.
- 2026-09-16 ALS drug failure intensifies scrutiny of Novartis R&D and M&A strategy, shareholder pressure persists
기업악재
Novartis halts ALS drug development after mid-stage trial failure영어 원문
Another R&D setback this year after del-desiran Phase III failure, ALS pipeline hit
첫날 +0.1% · 5일 후 +2.9%
이전 이벤트 9건›
애널리스트
HSBC: 투자의견 상향 → Hold
첫날 +0.0% · 5일 후 +2.5%
제품악재
Novartis del-desiran fails Phase 3, shares fall 10%영어 원문
HARBOR miss heightens pipeline risk concerns
첫날 -13.9% · 5일 후 +0.7%
›전개 과정 4회
- 2026-09-05 HORIZON trial failed to cut cardiovascular events despite Lp(a) reduction
- 2026-09-07 Multiple sources confirm pelacarsen missed primary endpoint, raising pipeline concerns
- 2026-09-08 After pelacarsen, del-desiran misses primary endpoint in HARBOR study, adding pipeline pressure
- 2026-09-09 HARBOR miss heightens pipeline risk concerns
제품호재
Novartis' Remibrutinib Meets Primary Endpoint in Phase III MS Studies, Slashes Relapse Rate영어 원문
Zacks confirms remibrutinib significantly reduced annualized relapse rates vs Aubagio in relapsing MS
첫날 +6.0% · 5일 후 -14.7%
›전개 과정 3회
- 2026-09-01 Oral BTK inhibitor beats teriflunomide in reducing relapse rates in RMS
- 2026-09-03 Both Phase III studies show superiority over Aubagio, strengthening oral MS franchise
- 2026-09-03 Zacks confirms remibrutinib significantly reduced annualized relapse rates vs Aubagio in relapsing MS
M&A·자금조달
Novartis signs up to $3.2B deal for Alteogen's drug delivery tech영어 원문
Gains subcutaneous injection tech, expands pipeline, but with high milestone payments
첫날 +0.8% · 5일 후 -15.4%
기업악재
Novartis Halts 8 CAR-T Trials After 3 Patient Deaths영어 원문
Multiple sources confirm trial pause in autoimmune/neurology cell therapy
첫날 +6.0% · 5일 후 -14.7%
실적
실적 발표영어 원문
Q2 net sales grew 1% in constant currencies to $14.4 billion; core operating income flat at $5.9 billion with 41.2% margin
첫날 +2.9% · 5일 후 +3.9%
실적호재
Novartis Q2 core operating profit beats expectations영어 원문
Q2 revenue and EPS beat estimates, core operating profit grew, FY26 guidance reaffirmed.
첫날 +2.9% · 5일 후 +3.9%
›전개 과정 2회
- 2026-07-21 Q2 core operating profit beat on strong cancer/MS drug sales, despite 50% Entresto drop
- 2026-07-21 Q2 revenue and EPS beat estimates, core operating profit grew, FY26 guidance reaffirmed.
제품
Novartis faces pipeline test with valuation premium in focus영어 원문
Reuters reports investors focus on three major drug trial readouts in H2 to justify premium valuation
첫날 -2.7% · 5일 후 +4.4%
M&A·자금조달
Multiple funds adjust Novartis stakes; Dimensional holds $1.24B영어 원문
Boston Common sold 5,150 shares; Dimensional cut 4.9% but retains $1.24B stake
첫날 -2.7% · 5일 후 +4.4%
›전개 과정 2회
- 2026-07-20 Boston Common cut 4.5%, Dimensional cut 4.9% but stake remains $1.24B
- 2026-07-20 Boston Common sold 5,150 shares; Dimensional cut 4.9% but retains $1.24B stake
방향별 정리 · 원문 링크
최근 2주간 X 신뢰 작성자 의견을 AI가 묶은 주장이며, 수치는 독립 작성자 수다. 언급량은 방향을 예측하지 않는다 · 투자 권유 아님
첫 댓글을 남겨 보세요
서로 존중 · 의견은 작성자 본인 책임 · 투자 권유 아님
사실과 의견을 구분해 표시 · 모든 항목 원문 확인 가능 · 본 정보는 투자 권유를 목적으로 하지 않으며, 투자 판단과 그 결과에 대한 책임은 투자자 본인에게 있습니다.
